{"id":"efavirenz-drug","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Efavirenz is a potent inhibitor of the HIV-1 reverse transcriptase enzyme, which is essential for the replication of the virus. By binding to the enzyme, efavirenz prevents the conversion of viral RNA into DNA, thereby inhibiting viral replication. This mechanism of action is specific to retroviruses such as HIV.","oneSentence":"Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by binding to the reverse transcriptase enzyme, preventing the replication of retroviruses such as HIV.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:40.122Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection in adults and children"},{"name":"Prevention of mother-to-child transmission of HIV"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT07482085","phase":"PHASE3","title":"Efavirenz for the Treatment of Creutzfeldt-Jakob Disease","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-03","conditions":"Creutzfeldt-Jakob Disease","enrollment":246},{"nctId":"NCT06823596","phase":"NA","title":"The T Cell Activator of Cell Killing (\"TACK\") IT ON\" STUDY","status":"RECRUITING","sponsor":"University of Toronto","startDate":"2025-01-14","conditions":"Hiv","enrollment":26},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT05789173","phase":"EARLY_PHASE1","title":"Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK","status":"RECRUITING","sponsor":"Indiana University","startDate":"2023-10-06","conditions":"Drug-Drug Interaction","enrollment":60},{"nctId":"NCT07341672","phase":"PHASE1","title":"A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2026-03-04","conditions":"Healthy Adult Subject","enrollment":80},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT02591420","phase":"PHASE1","title":"Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT05076682","phase":"PHASE2","title":"Reverse Triple Negative Immune Resistant Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-06-30","conditions":"Triple-negative Breast Cancer","enrollment":80},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT07193875","phase":"PHASE4","title":"Efavirenz (EFV) Intensification","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2023-02-09","conditions":"HIV","enrollment":7},{"nctId":"NCT02245022","phase":"PHASE2, PHASE3","title":"Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2017-03-14","conditions":"HIV, Pregnancy","enrollment":60},{"nctId":"NCT00964171","phase":"PHASE2","title":"Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2008-08","conditions":"Pancreatic Cancer","enrollment":19},{"nctId":"NCT06797674","phase":"PHASE1","title":"A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-02-10","conditions":"Healthy","enrollment":34},{"nctId":"NCT03800407","phase":"","title":"Contributing Factors for Poor HIV Treatment Response in Children With TB/HIV Coinfection","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-28","conditions":"Tuberculosis, Human Immunodeficiency Virus, Coinfection","enrollment":213},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT02284035","phase":"PHASE3","title":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2015-09-27","conditions":"AIDS","enrollment":75},{"nctId":"NCT01778413","phase":"PHASE4","title":"Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine","status":"COMPLETED","sponsor":"Anna Cruceta","startDate":"2013-06-03","conditions":"HIV","enrollment":61},{"nctId":"NCT05630885","phase":"PHASE2","title":"A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-05-30","conditions":"HIV-1-infection, Elevated Cardiovascular Risk","enrollment":110},{"nctId":"NCT06914869","phase":"PHASE1","title":"Drug-Drug Interaction Potential of Mavorixafor","status":"COMPLETED","sponsor":"X4 Pharmaceuticals","startDate":"2025-02-18","conditions":"Healthy Participants","enrollment":38},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT05909644","phase":"PHASE1","title":"An Open-label DDI Study of Omaveloxolone in Healthy Subjects","status":"COMPLETED","sponsor":"Biogen","startDate":"2023-07-05","conditions":"Healthy Adult Subjects","enrollment":20},{"nctId":"NCT03453840","phase":"PHASE4","title":"Extended Duration Artemether-lumefantrine Treatment for Malaria in Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-02-21","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":305},{"nctId":"NCT05044962","phase":"NA","title":"Kuwa Free! - Live Free!","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-26","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":700},{"nctId":"NCT00476606","phase":"","title":"A Prospective Cohort of Children With HIV Infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-03","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT04487145","phase":"PHASE4","title":"Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-11-23","conditions":"Drug-Drug Interaction, HIV Infection","enrollment":194},{"nctId":"NCT03249181","phase":"PHASE3","title":"Dolutegravir in Pregnant HIV Mothers and Their Neonates","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2018-01-22","conditions":"HIV-1-infection, Pregnancy Related","enrollment":268},{"nctId":"NCT02652260","phase":"PHASE2","title":"Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-03-04","conditions":"HIV-1, Central Nervous System","enrollment":86},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT03886766","phase":"NA","title":"Bioavailability Mechanistic Study of Hot-Melt Extruded Amorphous Solid Dispersions","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-04-30","conditions":"Biological Availability, Amorphous Solid Dispersions","enrollment":16},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT02403674","phase":"PHASE3","title":"Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-05","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":734},{"nctId":"NCT06698016","phase":"PHASE1","title":"A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-07-25","conditions":"Healthy","enrollment":16},{"nctId":"NCT01380080","phase":"PHASE4","title":"REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-10","conditions":"HIV Infection","enrollment":851},{"nctId":"NCT02722421","phase":"PHASE2","title":"Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-04-06","conditions":"HIV, Contraception","enrollment":28},{"nctId":"NCT06619288","phase":"","title":"Good-first: B/F/TAF As First-line ART","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-07-01","conditions":"HIV Infection","enrollment":630},{"nctId":"NCT03502005","phase":"PHASE4","title":"Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1","status":"COMPLETED","sponsor":"Midland Research Group, Inc.","startDate":"2018-03-01","conditions":"Human Immunodeficiency Virus","enrollment":100},{"nctId":"NCT03282799","phase":"PHASE2","title":"Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women","status":"COMPLETED","sponsor":"Catherine Anne Chappell","startDate":"2019-02-19","conditions":"HIV/AIDS, Contraception","enrollment":72},{"nctId":"NCT06294561","phase":"PHASE1","title":"TGRX-326 Pharmacokinetic Drug Interaction","status":"COMPLETED","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2024-03-04","conditions":"Non Small Cell Lung Cancer","enrollment":34},{"nctId":"NCT05067439","phase":"PHASE1","title":"A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-10-21","conditions":"Healthy Participants","enrollment":26},{"nctId":"NCT05883761","phase":"","title":"Birth Outcomes In Eswatini After Transition To Dolutegravir-Based Treatment","status":"COMPLETED","sponsor":"Elizabeth Glaser Pediatric AIDS Foundation","startDate":"2021-09-07","conditions":"Neural Tube Defects, Congenital Abnormalities, Teratogens","enrollment":50075},{"nctId":"NCT05995249","phase":"PHASE1","title":"A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-08-11","conditions":"Healthy Volunteers","enrollment":172},{"nctId":"NCT01837277","phase":"PHASE2, PHASE3","title":"Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients","status":"COMPLETED","sponsor":"Fundação Bahiana de Infectologia","startDate":"2017-12-15","conditions":"Severely Immunocompromised HIV Patients","enrollment":186},{"nctId":"NCT01886404","phase":"","title":"EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2013-12-01","conditions":"HIV Infection","enrollment":30},{"nctId":"NCT03537196","phase":"PHASE4","title":"DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-11-13","conditions":"Hepatitis C, Drug Use, Viral Hepatitis C","enrollment":979},{"nctId":"NCT03178084","phase":"PHASE3","title":"Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio","status":"COMPLETED","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2014-10-15","conditions":"HIV/AIDS","enrollment":721},{"nctId":"NCT04022967","phase":"PHASE3","title":"ANRS 12372 MODERATO Study","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-09-21","conditions":"HIV-1-infection","enrollment":480},{"nctId":"NCT01789879","phase":"PHASE2","title":"A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2014-03-04","conditions":"HIV, Contraception","enrollment":60},{"nctId":"NCT00350272","phase":"PHASE2","title":"Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2006-05","conditions":"HIV Infections","enrollment":76},{"nctId":"NCT02475915","phase":"PHASE1, PHASE2","title":"Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection","status":"COMPLETED","sponsor":"SEARCH Research Foundation","startDate":"2015-01","conditions":"Acute HIV Infection","enrollment":15},{"nctId":"NCT00775606","phase":"PHASE4","title":"Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2008-10","conditions":"Acquired Immune Deficiency Syndrome","enrollment":15},{"nctId":"NCT03982277","phase":"PHASE2","title":"Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy","status":"COMPLETED","sponsor":"Makerere University","startDate":"2019-04-30","conditions":"Tuberculosis","enrollment":130},{"nctId":"NCT03706885","phase":"PHASE1","title":"Efavirenz for Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Case Western Reserve University","startDate":"2018-05-05","conditions":"Alzheimer Disease, Early Onset","enrollment":5},{"nctId":"NCT03122262","phase":"PHASE3","title":"ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2017-01-16","conditions":"HIV-1 Infection","enrollment":1110},{"nctId":"NCT04296695","phase":"PHASE4","title":"Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-07-14","conditions":"HIV-1-infection","enrollment":250},{"nctId":"NCT05560360","phase":"PHASE1","title":"A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-11-04","conditions":"B-cell Tumors","enrollment":20},{"nctId":"NCT05330273","phase":"PHASE1","title":"Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-04-28","conditions":"Malaria","enrollment":14},{"nctId":"NCT01822522","phase":"PHASE1","title":"Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-06-21","conditions":"Advanced Malignant Solid Neoplasm, HIV Infection, Metastatic Malignant Solid Neoplasm","enrollment":36},{"nctId":"NCT04708496","phase":"PHASE4","title":"Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2021-01-18","conditions":"HIV Coinfection, Malaria","enrollment":888},{"nctId":"NCT04334915","phase":"PHASE2","title":"Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-11-22","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT03532425","phase":"PHASE4","title":"B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2018-10-29","conditions":"HIV-1-infection","enrollment":28},{"nctId":"NCT03048422","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-01-19","conditions":"HIV Infections","enrollment":643},{"nctId":"NCT01815580","phase":"PHASE4","title":"HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-07","conditions":"HIV","enrollment":225},{"nctId":"NCT05525156","phase":"PHASE2","title":"The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy","status":"SUSPENDED","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2020-03-02","conditions":"Hiv, Cardiovascular Diseases","enrollment":454},{"nctId":"NCT04459598","phase":"PHASE1","title":"A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2020-08-19","conditions":"Healthy Subjects, Drug-drug Interaction, Pharmacokinetics","enrollment":32},{"nctId":"NCT04504045","phase":"PHASE1","title":"Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"University of Southern Denmark","startDate":"2020-09-01","conditions":"Diabetes Mellitus, Type 2","enrollment":10},{"nctId":"NCT04429152","phase":"PHASE3","title":"ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance","status":"UNKNOWN","sponsor":"Professor Francois Venter","startDate":"2021-02-09","conditions":"HIV-1-infection","enrollment":25},{"nctId":"NCT04424264","phase":"PHASE1","title":"The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2019-12-05","conditions":"HIV-1-infection, Tuberculosis","enrollment":18},{"nctId":"NCT00964002","phase":"PHASE2","title":"Efavirenz in Treating Patients With Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2008-05","conditions":"Prostate Cancer","enrollment":61},{"nctId":"NCT04840641","phase":"PHASE1","title":"Flucloxacillin as an Inducer of CYP-enzymes","status":"COMPLETED","sponsor":"University of Southern Denmark","startDate":"2021-03-25","conditions":"Healthy Volunteers, Drug Drug Interaction","enrollment":14},{"nctId":"NCT02778204","phase":"PHASE1","title":"Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-05","conditions":"HIV Infections","enrollment":47},{"nctId":"NCT03819114","phase":"PHASE2","title":"Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2019-05-06","conditions":"HIV Infections, Tuberculosis","enrollment":122},{"nctId":"NCT05141422","phase":"PHASE1","title":"A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-12-13","conditions":"Human Immunodeficiency Virus Infection","enrollment":20},{"nctId":"NCT03158857","phase":"","title":"Hepatitis C Treatment Study in Myanmar","status":"WITHDRAWN","sponsor":"Myanmar Oxford Clinical Research Unit","startDate":"2022-01","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT04973020","phase":"PHASE1","title":"A Drug-drug Interaction Study of SHR6390 on Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-09-01","conditions":"Advanced Solid Tumor","enrollment":20},{"nctId":"NCT00260078","phase":"PHASE1, PHASE2","title":"Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT01571414","phase":"PHASE1","title":"Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-05","conditions":"Tuberculosis","enrollment":52},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT00016718","phase":"PHASE1, PHASE2","title":"Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-08","conditions":"HIV Infections","enrollment":43},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT00802802","phase":"PHASE1","title":"Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-02-10","conditions":"HIV Infections, Tuberculosis","enrollment":67},{"nctId":"NCT00051090","phase":"NA","title":"Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B","enrollment":""},{"nctId":"NCT00001086","phase":"PHASE2","title":"A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00992069","phase":"PHASE1","title":"Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-12","conditions":"Tuberculosis, HIV","enrollment":37},{"nctId":"NCT00100581","phase":"NA","title":"Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":2},{"nctId":"NCT00001087","phase":"PHASE2","title":"The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00005762","phase":"NA","title":"Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-03","conditions":"HIV Infections","enrollment":90},{"nctId":"NCT00050895","phase":"PHASE3","title":"Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":775},{"nctId":"NCT00000914","phase":"NA","title":"A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":800},{"nctId":"NCT00000912","phase":"PHASE2","title":"A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":475},{"nctId":"NCT00000893","phase":"PHASE1","title":"Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1997-10","conditions":"HIV Infections","enrollment":103},{"nctId":"NCT00000939","phase":"PHASE2","title":"A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT00000885","phase":"PHASE2","title":"Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":440},{"nctId":"NCT01435018","phase":"PHASE3","title":"Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-10-01","conditions":"HIV-1 Infection","enrollment":334},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT03374358","phase":"PHASE4","title":"Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2018-01-10","conditions":"HIV Seropositivity, Metabolic Syndrome, Fatty Liver","enrollment":45},{"nctId":"NCT02777229","phase":"PHASE3","title":"Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-07","conditions":"HIV-1 Infection","enrollment":616},{"nctId":"NCT01147107","phase":"PHASE4","title":"Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection","status":"COMPLETED","sponsor":"University of Hawaii","startDate":"2014-02","conditions":"Hepatitis C, Chronic, HIV Infection","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"efavirenz (drug)","genericName":"efavirenz (drug)","companyName":"French National Agency for Research on AIDS and Viral Hepatitis","companyId":"french-national-agency-for-research-on-aids-and-viral-hepatitis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by binding to the reverse transcriptase enzyme, preventing the replication of retroviruses such as HIV. Used for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}